{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+Blocker&page=2",
    "query": {
      "intervention": "H1 Blocker",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+Blocker&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T16:01:13.139Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06824467",
      "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H1 receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "H2 receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen (or equivalent)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone (or equivalent)",
          "type": "DRUG"
        },
        {
          "name": "Steroid mouthwash (dexamethasone or equivalent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 770,
      "start_date": "2025-04-09",
      "completion_date": "2032-11-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06824467"
    },
    {
      "nct_id": "NCT05858216",
      "title": "First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Voice Disorder Due to Iatrogenic Factor"
      ],
      "interventions": [
        {
          "name": "Chlor-Trimeton.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Auburn University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 8,
      "start_date": "2023-06-13",
      "completion_date": "2024-04-23",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 1,
      "location_summary": "Auburn, Alabama",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05858216"
    },
    {
      "nct_id": "NCT06072157",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "AK006-IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo-IV",
          "type": "DRUG"
        },
        {
          "name": "AK006-SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo-SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allakos Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 136,
      "start_date": "2023-08-28",
      "completion_date": "2025-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 19,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072157"
    },
    {
      "nct_id": "NCT01443442",
      "title": "Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "bepotastine besilate, 1.5%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California College of Optometry at Marshall B. Ketchum University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 2,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443442"
    },
    {
      "nct_id": "NCT04743661",
      "title": "131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Medulloblastoma",
        "Recurrent Ependymoma"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Omburtamab I-131",
          "type": "DRUG"
        },
        {
          "name": "Liothyronine",
          "type": "DRUG"
        },
        {
          "name": "SSKI",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Antipyretic",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "anti-emetics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 62,
      "start_date": "2022-04-04",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743661"
    },
    {
      "nct_id": "NCT06455202",
      "title": "A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "barzolvolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matching placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 976,
      "start_date": "2024-07-19",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 63,
      "location_summary": "Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06455202"
    },
    {
      "nct_id": "NCT01382940",
      "title": "A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "antihistamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 351,
      "start_date": "2011-07-26",
      "completion_date": "2013-01-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01382940"
    },
    {
      "nct_id": "NCT07778472",
      "title": "Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tripelennamine",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control Cream Base",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palm Beach Atlantic University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 37,
      "start_date": "2025-02-24",
      "completion_date": "2025-09-18",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 1,
      "location_summary": "West Palm Beach, Florida",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07778472"
    },
    {
      "nct_id": "NCT00000363",
      "title": "Acute Otitis Media: Adjuvant Therapy to Improve Outcome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Otitis Media"
      ],
      "interventions": [
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Deafness and Other Communication Disorders (NIDCD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "2 Months to 1 Year"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2006-04-24",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000363"
    },
    {
      "nct_id": "NCT05263206",
      "title": "Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fexofenadine (loratadine if not available)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 284,
      "start_date": "2022-02-15",
      "completion_date": "2027-08-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-15T16:01:13.139Z",
      "location_count": 18,
      "location_summary": "Bakersfield, California • La Jolla, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Belleair",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05263206"
    }
  ]
}